Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $338.65 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.58 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 15.79%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Botanix Pharmaceuticals Ltd (ASX: BOT)
    Latest News

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    If you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 now

    You don't have to have 100% winners in your portfolio. Just check out this star, which could have carried the…

    Read more »

    Man in a cannabis greenhouse looks unhappy and puts his thumb down.
    Cannabis Shares

    Why are these 2 ASX cannabis stocks sputtering today?

    Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    Why Botanix, Nick Scali, Resolute, and Sayona Mining shares are dropping

    These ASX shares are under pressure on Tuesday. But why?

    Read more »

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Cannabis Shares

    Guess which ASX cannabis share is crashing 36% following an FDA blow

    Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

    Read more »

    A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
    Cannabis Shares

    Could ASX cannabis shares be set for a resurgence?

    The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

    Read more »

    A young woman holding her phone smiles broadly and looks excited, after receiving good news.
    Cannabis Shares

    This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

    Investors are very excited about this cannabis stock.

    Read more »

    Man slipping over on banana skin
    Healthcare Shares

    Here's why the Botanix (ASX:BOT) share price is slipping today

    Botanix was busy over the fourth quarter, but its accomplishments aren't being well received by the market.

    Read more »

    little green pharma share price represented by cannabis leaf character jumping cheerfully
    Cannabis Shares

    Blazing it? How the top ASX cannabis shares performed in FY21

    How did ASX cannabis shares fare in FY21?

    Read more »

    rising asx share price represented by happy woman dancing excitedly
    Share Gainers

    The Botanix (ASX:BOT) share price jumped 20% today

    This cannabis focused biotech company was on form on Friday...

    Read more »

    A man holds his hands out and shrugs.
    Share Market News

    What's with the Botanix (ASX:BOT) share price today?

    The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is relatively stagnant on the company's half-year results and management expansion.

    Read more »

    falling asx share price represented by business man giving thumbs down gesture
    Share Market News

    Botanix (ASX:BOT) share price falls despite big tax refund

    The Botanix Pharmaceuticals (ASX: BOT) share price is edging higher this morning. We look at the company's latest release.

    Read more »

    asx share price increase represented by golden dollar sign rocketing out from white domes of lithium
    Share Gainers

    Why the Botanix (ASX:BOT) share price is rocketing 31% higher today

    The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is rocketing 31% higher on Wednesday. Here's what is happening...

    Read more »

    BOT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Botanix Pharmaceuticals Ltd

    Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietarydrug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

    BOT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Apr 2024 $0.22 $-0.01 -4.44% 1,501,920 $0.22 $0.23 $0.22
    19 Apr 2024 $0.23 $0.00 0.00% 2,434,185 $0.23 $0.23 $0.22
    18 Apr 2024 $0.23 $0.01 4.55% 1,589,306 $0.23 $0.23 $0.22
    17 Apr 2024 $0.22 $0.02 9.76% 2,155,140 $0.21 $0.23 $0.21
    16 Apr 2024 $0.21 $-0.01 -4.76% 2,190,238 $0.21 $0.22 $0.21
    15 Apr 2024 $0.21 $0.01 4.88% 2,236,722 $0.21 $0.22 $0.21
    12 Apr 2024 $0.21 $-0.01 -4.76% 2,658,274 $0.21 $0.22 $0.21
    11 Apr 2024 $0.21 $-0.01 -4.65% 3,937,250 $0.22 $0.22 $0.21
    10 Apr 2024 $0.22 $-0.01 -4.44% 3,699,169 $0.23 $0.23 $0.22
    09 Apr 2024 $0.23 $0.00 0.00% 1,587,704 $0.23 $0.23 $0.22
    08 Apr 2024 $0.23 $-0.01 -4.26% 3,551,222 $0.23 $0.24 $0.22
    05 Apr 2024 $0.24 $0.00 0.00% 2,487,816 $0.24 $0.24 $0.23
    04 Apr 2024 $0.24 $-0.01 -4.17% 2,728,815 $0.24 $0.24 $0.23
    03 Apr 2024 $0.24 $0.01 4.26% 3,755,528 $0.23 $0.24 $0.22
    02 Apr 2024 $0.24 $0.01 4.44% 3,585,357 $0.23 $0.24 $0.22
    28 Mar 2024 $0.23 $0.01 4.55% 9,851,734 $0.23 $0.24 $0.22
    27 Mar 2024 $0.22 $0.02 10.00% 8,415,323 $0.20 $0.22 $0.20
    26 Mar 2024 $0.20 $0.01 5.26% 2,295,418 $0.19 $0.20 $0.19

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 May 2023 Matthew (Matt) Callahan Exercise 1,166,667 $99,166
    Conversion of securities. 1,166,667 Performance Rights
    18 May 2023 Matthew (Matt) Callahan Buy 1,166,667 $99,166
    Conversion of securities.
    18 May 2023 H. William Bosch Exercise 500,000 $42,500
    Conversion of securities. 500,000 Performance Rights
    18 May 2023 H. William Bosch Buy 500,000 $42,500
    Conversion of securities.
    18 May 2023 Vince Ippolito Exercise 2,000,000 $170,000
    Conversion of securities. 2,000,000 Performance Rights
    18 May 2023 Vince Ippolito Buy 2,000,000 $170,000
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Matthew (Matt) Callahan Executive Director Feb 2020
    Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and co-inventor of many of the Company's Permetrex enabled products. Mr Callahan was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to US private equity investors. He has more than 25 years legal, IP and investment management experience.
    Dr Stewart James Washer Non-Executive Director Feb 2019
    Dr Washer has CEO and experience in medical biotech and cannabinoid companies. Dr Washer has held a number of board positions in the past, including chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors. He was also a Senator with Murdoch University and was a director of AusBiotech Ltd.
    Dr H. William Bosch Executive Director Jul 2016
    Dr Bosch is an accomplished pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA approved prescription drug products. Earlier in his career Dr. Bosch was a pioneer in the application of nanotechnology to pharmaceutical product development. He served as a co founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the successful development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
    Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
    Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including over 20 years' experience in dermatology. He recently served as President and Chief Operating Officer of Dermavant Sciences, a biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company. During his time at Anacor he was responsible for building the marketing and sales functions, and developing the company's product portfolio, as well as playing a key role in the US$5.2bn sale to Pfizer. Earlier in his career, Mr Ippolito launched multiple new dermatology products during his tenure at Medicis Pharmaceutical Corporation, an industry-leading dermatology company. Mr. Ippolito served in multiple key executive roles, including Chief Commercial Officer, General Manager of Dermatology products, Senior Vice President of North American Sales and Executive Vice President, Sales and Marketing. Mr Ippolito played a key role in the sale of Medicis to Valeant for US$2.6bn in 2012 and he went on to serve as Senior Vice President, General Manager, Aesthetics
    Mr Daniel Sharp Non-Executive Director Mar 2022
    Mr Sharp is an investment banker with more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has a network of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity and has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
    Ms Susan Patricia Park Company Secretary Apr 2023
    Dr Howie McKibbon Chief Executive Officer Aug 2023
    Howie McKibbon Chief Executive Officer
    Susan Patricia Park Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 139,690,538 9.83%
    Shenasaby Investments Pty Ltd <The Shenasaby A/C> 74,586,791 5.25%
    Caperi Pty Ltd <Caperi A/C> 52,573,784 3.70%
    Citicorp Nominees Pty Limited 51,527,974 3.63%
    Dr Henry William Bosch 18,836,702 1.33%
    Zenith Pacific Limited 17,972,222 1.26%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 17,303,656 1.22%
    J P Morgan Nominees Australia Pty Limited 17,007,647 1.20%
    Hsbc Custody Nominees (Australia) Limited 16,843,169 1.19%
    Bnp Paribas Noms Pty Ltd <Drp> 14,818,037 1.04%
    Ubs Nominees Pty Ltd 14,148,149 1.00%
    Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 13,000,000 0.91%
    Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 10,560,000 0.74%
    Lightview Asset Pty Ltd 9,350,000 0.66%
    Zanya Nominees Pty Ltd<Jls Superannuation A/C> 8,984,545 0.63%
    Mr Vincent Peter Ippolito 8,801,644 0.62%
    Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 8,500,000 0.60%
    Mr Gary Charles Jones &Mrs Stephanie May Jones <G & S Jones Super Fund A/C> 8,000,000 0.56%
    343 Pty Ltd <343 Capital A/C> 7,125,667 0.50%
    Mr Stephane Nicolas Fayd Herbe <Fayd'Herbe Family A/C> 7,113,141 0.50%